RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $295 to $273.
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $295 to $273.